The role of serotonin in antipsychotic drug action

Neuropsychopharmacology

Volumn 21, Issue , 1999, Pages 106S-115S

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CHLORPROMAZINE; CLOZAPINE; CYPROHEPTADINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EPLIVANSERIN; FLESINOXAN; ILOPERIDONE; KETAMINE; LOXAPINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; QUETIAPINE; RISPERIDONE; RITANSERIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; SERTINDOLE; SULPIRIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

AFFECTIVE NEUROSIS; AGRANULOCYTOSIS; AMNESIA; COGNITION; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEROTONIN RELEASE; THERAPY RESISTANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE ANTAGONISTS; HUMANS; PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0032868798     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00046-9     Document Type: Article

References (82)

1. Abi-Dargham A, Lamelle M, Aghajanian GK (1997): The role of serotonin in the pathophysiology and treatment of schizophrenia. J NeuropsyClinNeurosci 9:1-17
2. 1a agonist 8-oH-DPAT in the rat. PharmacolToxicol 64:3-5
3. Altman HJ, Stone WS, Ögren S (1987): Evidence for a possi-ble functional interaction between serotonergic and cho-linergic mechanism in memory retrieval. Behav Neural Biol 48:49-62
4. Altar CA, Wasley AM, Neale RF, Stone GA (1986): Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain. Brain Res Bull 16:517-525
5. Arndt J, Skarsfeldt T (1998): Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.Neuropsychopharmacology 18:63-101
6. Arvanitis LA, Miller BG (1997): Multiple fixed dose of "Sero-quel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.BiolPsychia-try 42:233-246
7. Barbato L, Monge A, Stocchi F, Nordera G (1996): Melperone in the treatment of iatrogenic psychosis in Parkinson's Disease. ClinNeuropharmacol 11:201-207
8. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998): Risperidone versus clozapine in treatment resistant chronic schizophrenia: A random-ized double-blind study. The Risperidone Study Group. Am J Psychiatry 155:499-504
9. Buhot M-C (1997): Serotonin receptors in cognitive behav-iors. CurrOpinNeurobiol 7:243-254
10. Calabrese J, Kimmel SE, Woyshiville M, Rapport WJ, Trivedi CJ, Meltzer HY (1996): Clozapine in treatment refractory mania. Am J Psychiatry 153:759-764
11. Casey DE (1991): Extrapyramidal syndromes in nonhuman primates: Typical and atypical neuroleptics. Psycho-pharmacol Bull 27:47-50
12. Casey DE (1993): Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112(Suppl 1): S55-S59
13. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Counaris C, Zaremba S (1998a): Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 155:914-920
14. Conley RR, Kelly DL, Gale EA (1998b): Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schiz Res 33:95-101
15. 1a and 5-HT2 receptors? PharmacolBiochemBehav 26:901-906
16. Deutch AY, Duman RS (1996): The effects of antipsychotic drugs on fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characteriza-tion. Neuroscience 70:377-389
17. Ferre S, Artigas F (1995): Clozapine decreased serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci Lett 187:61-64
18. Fiorella D, Helsley S, Rabin RA, Winter JC (1995): The interactions of typical and atypical antipsychotics with the (-)2, 5-dimethoxy-4-methamphetamine (DOM) discrimi-native stimulus. Neuropharmacology 34:1297-303
19. Ganguli R, Brar JS (1998): The effects of risperidone and olanzapine on the indications for clozapine. Psycho-pharmacol Bull 34(1):83-87
20. Gleason SC, Shannon HE (1997): Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129:79-84
21. Guo N, Klitenick MA, Tham CS, Fibiger HC (1995): Receptor mechanism mediating clozapine-induced c-fos expression in the forebrain. Neuroscience 65:747-756
22. 1a receptor in working memory. J Psychopharmacol 9:242-250
23. Hertel P, Nomikos G, Schilstrom B, Arborelius L, Svensson TH (1997): Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat fron- tal cortex: Role of a2- adrenoceptor antagonism. Neu-ropsychopharmacology 17:44-55
24. Ichikawa J, Kuroki T, Dai J, Meltzer, HY (1998): Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 351:163-171
25. 1a receptor agonist, inhibits amphet-amine-induced serotonin and dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol 287:179-184
26. 2a/2c receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Bram Res 698:204-208
27. Ishikane T, Kusumi I, Matsubara R, Matsubara S, Koyama T (1997): Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Eur J Pharmacol 321:163-169
28. Jakab RL, Goldman-Rakic P (1998): 5-Hydroxytryptamine 2a serotonin receptors in the primate cerebral cortex: Possi-ble site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. ProcNatlAcad Sci USA 95:735-740
29. Kalkman HO, Neumann V, Hoyer D, Tricklebank MD (1998): The role of a2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 124:1550-1556
30. Kane J, Honigfeld G, Singer J, Meltzer HY Clozaril Collaborative Study Group (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
31. Kapur S, Remington G (1996): Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476
32. Kinon BJ, Lieberman JA (1996): Mechanisms of action of atypical antipsychotic drugs—A critical analysis [review]. Psychopharmacology 124:2-34
33. Kuroki T, Meltzer HY, Ichikawa J (1999): Effects of antipsy-chotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J PharmacolExpTher 288:774-781
34. Leslie RA, Moorman JM, Coulson A, Grahame-Smith DG (1993): Serotonin2/1C receptor activation causes a local-ized expression of the immediate-early gene c-fos in rat brain: Evidence for involvement of dorsal raphe nucleus projection fibres. Neuroscience 53:457-463
35. Maes M, Meltzer HY (1995): Chapter 81. The serotonin hypothesis of depression. In Nemeroff CB, Kupfer D (eds), Psychopharmacology: The Fourth Generation of Progress. New York, NY, Raven Press, pp 933-944
36. Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835
37. 2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm 104:561-564
38. Masellis FM, Macciardi FM, Meltzer HY, Lieberman JA, Sevy S, Cavazzoni P, Cola P, Howard A, Badri F, Nothen M, Kalow W, Kennedy JL (1998): Serotonin subtype 2 receptor genese and clinical response to clozapine in schizophrenic patients. Neuropsychopharmacology 19:123-132
39. Meltzer HY (1979): The clozapine story. In Hertzman M, Feltner DE (eds), The Handbook of Psychopharmacol-ogy Trials. New York, NY, New York University Press, pp 137-156
40. Meltzer HY (1992): Treatment of the neuroleptic non-respon-sive schizophrenic patient. Schiz Bull 18:515-542
41. Meltzer HY (1997): Treatment-resistant schizophrenia—The role of clozapine. Curr Med Res Op 14:1-20
42. Meltzer HY, Fatemi SH (1996): The role of serotonin in schizophrenia and the mechanism of action on anti-psy-chotic drugs. In Kane JM, Moller HJ, Awouters F (eds), Serotonergic Mechanisms in Antipsychotic Treatment. New York, NY, Marcel Decker, pp 77-107
43. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995): Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: A high potency effect of clozapine. Neuropsychopharmacology 12:39-45
44. Meltzer HY, Lee MA, Ranjan R, Mason ED, Cola PA (1996a): Relapse following clozapine withdrawal: Effect of cyproheptadine plus neuroleptic. Psychopharmacology 124:176-187
45. Meltzer HY, Maes M (1995): Pindolol pretreatment blocks stimulation by metachlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Psychiatry Res 58:89-98
46. Meltzer HY, Matsubara S, Lee J-C (1989): Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Phar-macolExpTher 251:238-246
47. Meltzer HY, McGurk SR (in press): The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schiz Bull
48. Meltzer HY, Nash JF (1991): Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604
49. Meltzer HY, Okayli G (1995): The reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry 152:183-190
50. Meltzer HY, Roth B, Thompson P (1996b): Serotonin and dopamine receptor affinites predict atypical antipsy-chotic drug (aAd) activity. NeurosciAbstr 22:480
51. Meneses A, Hong E (1997): A pharmacological analysis of serotonergic receptors: Effect of their activation of blockade in learning. ProgNeuropsychopharmacolBiol Psychiatry 21:273-296
52. Millan MJ, Dekeyne A, Gobert A (1998a): Serotonin (5-HT)2c receptors inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 27:953-955
53. 1a agonist properties. 1. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J PharmacolExpTher 286:1341-1355
54. Möller HJ, Muller H, Borison RL, Schooler NR, Chouinard G (1995): A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Euro Arch Psy-chiatryClinNeurol 245:45-49
55. Mountjoy CQ, Baldacchino AM, Stubbs JH (1998): British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 156:158-159
56. 1a receptors: A [35 S]GTP7 S. Eur J Pharmacol 355:245-256
57. Parada MA, Hernandez L, Puig de Parada M, Rada P, Murzi E (1997): Selection action of acute systemic clozapine on acetylcholin release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J Pharma-col ExpTher 281:582-588
58. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Ker-win RW (1997a): Limbic selectivity of clozapine. Lancet 350:490-491
59. Pilowsky LS, O'Connell PO, Davies N, Busatto GH, Costa DA, Murray RM, Ell pJ, Kerwin RW (1997b): In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole—A 223I IBZM single photon emission tomography (SPET) study. Psychopharmacology 130:152-158
60. Prinssen EPM, Kleven MS, Koek W (1996): Effects of dopamine antagonists in a two-way active avoidance proce-dure in rats: Interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 128:191-197
61. Protais P, Chagraoui A, Arbaoui J (1994): Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclo-pride and clozapine in rodent. Eur J Pharmacol 271:167-173
62. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, Breier A, Tollefson D Canadian Collaborative Group for Research on Cognition in Schizophrenia (1998): Olanzap-ine vs. risperidone and haloperidol in the treatment of cognitive impairment in schizophrenia. Presented at the American College of Neuropsychopharmacology Annual Meeting. Las Croabas, Puerto Rico, December 14-18, 1998
63. Rasmussen K, Aghajanian GK (1988): Potency of antipsy-chotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 bind-ing affinity. Neuropsychopharmacology 1:101-107
64. Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Neliat G, Labeeuw B, Le Fur G, Soubrie pG, Breliere JC (1992): Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonists. J Pharma-col ExpTher 262:759-768
65. Robertson GS, Matsumura H, Fibiger HC (1994): Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharma-col ExpTher 271:1058-1066
66. 1a recep-tor activation. Eur J Pharmacol 338:R3-R5
67. Roth BL, Ciaranello RD, Meltzer HY (1992): Binding of typi-cal and atypical antipsychotic agents with transiently expressed 5-HT1c receptors. J PharmacolExpTher 260:1361-1365
68. Roth B, Craigo SC, Choudhary MS, Ulue A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994): Binding of typical and atypical antipsychotic agents to 5-hydroxy-tryptamine-6 and 5-hydroxytryptamine-7 receptors. J PharmacolExpTher 268:1401-1410
69. Ruotsalainen S, Sirvio J, Jäkälä P, Puumala T, MacDonald E, Riekkin P Sr. (1997): Differential effect of three 5-HT receptor antagonists on the performance of rats in atten-tional and working memory tasks. Eur J Neuropsycho-pharmacol 7:99-108
70. Sapolsky RM (1994): The physiological relevance of gluco-corticoid endangerment of the hippocampus. Ann NY AcadSci USA 746:294-304
71. 2a receptors in antipsychotic activity. Life Sci 56:2209-2222
72. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, DeLoore K, Leysen JE (1996): Risperidone compared with new and reference antipsy-chotic drugs: In vitro and in vivo receptor binding. Psy-chopharmacology 124:57-73
73. Shipley J (1998): M100907 Phase IIB Trial. Presented at Hoechst Marion Roussel Conference on 100907. West Palm Beach Florida, April 1998
74. 2c receptors sub-types in the control of haloperidol-induced release of dopamine in the rat striatum. NeurosciAbstr 24:48-4
75. 2a/2c and 5-HT3 receptors. NeurosciAbstr 23:907-8
76. Tollefson GD, Sanger TM. (1996): Negative symptoms: A path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466-474
77. 2a antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry
78. 2a receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17:2785-2795
79. Varty GB, Higgins GA (1995): Reversal of a dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ket-anserin. Eur J Pharmacol 287:201-205
80. Wadenberg ML (1992): Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Trans 89:49-59
81. Wadenberg ML, Ahlenius S (1991): Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy. J Neural Trans [Gen Sect] 83:43-53
82. 1a autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 34:495-499